Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Forigerimod - ImmuPharma

Drug Profile

Forigerimod - ImmuPharma

Alternative Names: CEP-33457; IPP-201101; Lupuzor; peptide P140; Rigerimod; SyB 1001

Latest Information Update: 23 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS
  • Developer Cephalon; ImmuPharma
  • Class Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Phase III Systemic lupus erythematosus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Apr 2018 Interim efficacy and adverse events data from a pivotal phase III trial in systemic lupus erythematosus released by ImmuPharma
  • 29 Jan 2018 ImmuPharma initiates a phase III trial in Systemic lupus erythematosus in USA, France, Puerto Rico (SC) (NCT03427151)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top